Hakushi Kim

Hakushi Kim

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
HKHakushi Kim
Hakushi Kim
Tomoyoshi KomiyamaTomoyoshi Komiyama
Tomoyoshi Komiyama
CIChie Inomoto
Chie Inomoto
HKHiroshi Kamiguchi
Hiroshi Kamiguchi
HKHiroshi Kajiwara
Hiroshi Kajiwara
TTToshiro Terachi
Toshiro Terachi
We analyzed mutations in the mitochondrial ND1 gene to determine their association with clinicopathological parameters and postoperative recurrence of renal cell carcinoma (RCC) in Japanese patients. Among 62 RCC cases for which tumor pathology was confirmed by histopathology, ND1 sequencing revealed the presence of 30 mutation sites in 19 cases. Most mutations were heteroplasmic, with 16 of 19 cases harboring one or more heteroplasmic sites. Additionally, 12 sites had amino acid mutations, which were frequent in 10 of the cases. The 5-year recurrence-free survival (RFS) rate was significantly worse in patients with tumors >40 mm in diameter (p = 0.0091), pathological T (pT) stage ≥3 (p = 0.0122), Fuhrman nuclear atypia grade ≥III (p = 0.0070), and ND1 mutations (p = 0.0006). Multivariate analysis using these factors revealed that mutations in ND1 were significantly associated with the 5-year RFS rate (p = 0.0044). These results suggest a strong correlation between the presence of ND1 mutations in cancer tissue and postoperative recurrence of localized RCC in Japanese patients.

28 February 2018 in International Journal of Oncology
Verified
Journal Article
Open access
PDF file
HKHakushi Kim
Hakushi Kim
CIChie Inomoto
Chie Inomoto
TUTakato Uchida
Takato Uchida
HFHiroyuki Furuya
Hiroyuki Furuya
Tomoyoshi KomiyamaTomoyoshi Komiyama
Tomoyoshi Komiyama
AMAkira Miyajima
Akira Miyajima
The aim of the present study was to evaluate the validity of potential prognostic parameters of clear cell renal cell carcinoma (ccRCC) recommended by the 2012 International Society of Urological Pathology (ISUP) Consensus Conference in the Japanese population. We reviewed 406 Japanese patients with localized or locally advanced ccRCC who underwent curative surgery during 2004-2014 at Tokai University Hospital (Isehara, Japan) and were followed up for >2 years after surgery. A single pathologist reviewed all the histological slides. Morphological subtype and pathological T stage were reassigned according to the 2016 World Health Organization and TNM classifications. Sarcomatoid differentiation (SD), rhabdoid differentiation (RD), tumor necrosis (TN) and microvascular invasion (MVI) were assessed according to the 2012 ISUP recommendations. Nuclear grade was reclassified according to both the Fuhrman and the ISUP grading systems. Recurrence‑free survival (RFS) and cancer-specific survival (CSS) were assessed through univariate and multivariate analyses. According to the Fuhrman grading system (group Fuhrman), TN and MVI were independent risk factors for postoperative recurrence in the multivariate analysis using the Cox proportional hazards model. According to the ISUP grading system (group ISUP), TN and MVI were independent risk factors for postoperative recurrence. In group Fuhrman, age, Fuhrman grade and TN were independent risk factors for CSS. In group ISUP, age, ISUP grade, and TN were independent risk factors for CSS. Furthermore, the group that was upgraded from Fuhrman grade 2 to ISUP grade 3 exhibited poorer CSS compared with the group that was reclassified from Fuhrman grade 2 to ISUP grade 2 (non-upgraded). Regardless of the nuclear grade, TN remained an independent predictor of RFS and CSS. To the best of our knowledge, this is the first report to prove the correlation between the 2012 ISUP recommendations and clinical outcomes in a Japanese ccRCC cohort. TN and upgrading to ISUP grade 3 were found to be potentially useful independent indicators of postoperative prognosis.

8 April 2022 in International Journal of Urology
Verified
Journal Article
Closed access
TKTatsuo Kano
Tatsuo Kano
HKHakushi Kim
Hakushi Kim
MKMasayoshi Kawakami
Masayoshi Kawakami
MNMasahiro Nitta
Masahiro Nitta
MHMasanori Hasegawa
Masanori Hasegawa
AMAkira Miyajima
Akira Miyajima

2 December 2019 in Genes
Verified
Journal Article
Open access
PDF file
HKHakushi Kim
Hakushi Kim
Tomoyoshi KomiyamaTomoyoshi Komiyama
Tomoyoshi Komiyama
MNMasahiro Nitta
Masahiro Nitta
YKYoshiaki Kawamura
Yoshiaki Kawamura
MHMasanori Hasegawa
Masanori Hasegawa
AMAkira Miyajima
Akira Miyajima
Renal cell carcinoma (RCC) is associated with various genetic alterations. Although whole-genome/exome sequencing analysis has revealed that nuclear genome alterations are associated with clinical outcomes, the association between nucleotide alterations in the mitochondrial genome and RCC clinical outcomes remains unclear. In this study, we analyzed somatic mutations in the mitochondrial D-loop region, using RCC samples from 61 consecutive patients with localized RCC. Moreover, we analyzed the relationship between D-loop mutations and NADH dehydrogenase subunit 1 (MT-ND1) mutations, which we previously found to be associated with clinical outcomes in localized RCC. Among the 61 localized RCCs, 34 patients (55.7%) had at least one mitochondrial D-loop mutation. The number of D-loop mutations was associated with larger tumor diameter (>32 mm) and higher nuclear grade (≥ISUP grade 3). Moreover, patients with D-loop mutations showed no differences in cancer-specific survival when compared with patients without D-loop mutations. However, the co-occurrence of D-loop and MT-ND1 mutations improved the predictive accuracy of cancer-related deaths among our cohort, increasing the concordance index (C-index) from 0.757 to 0.810. Thus, we found that D-loop mutations are associated with adverse pathological features in localized RCC and may improve predictive accuracy for cancer-specific deaths when combined with MT-ND1 mutations.

21 August 2017 in International Urology and Nephrology
Verified
Journal Article
Closed access
PDF file
HKHakushi Kim
Hakushi Kim
SNSerina Nakajima
Serina Nakajima
YKYoshiaki Kawamura
Yoshiaki Kawamura
SSSunao Shoji
Sunao Shoji
AHAkio Hoshi
Akio Hoshi
AMAkira Miyajima
Akira Miyajima

13 April 2022 in Biology
Verified
Journal Article
Open access
PDF file
Tomoyoshi KomiyamaTomoyoshi Komiyama
Tomoyoshi Komiyama
HKHakushi Kim
Hakushi Kim
MTMasayuki Tanaka
Masayuki Tanaka
SISanae Isaki
Sanae Isaki
KYKeiko Yokoyama
Keiko Yokoyama
HKHiroyuki Kobayashi
Hiroyuki Kobayashi
This study aimed to clarify whether genetic mutations participate in renal cell carcinoma (RCC) metastasis to the adrenal gland (AG). Our study analyzed whole mitochondrial gene and ribonucleic acid sequencing (RNA-seq) data from a male patient in his 60s with metastatic RCC. We confirmed common mutation sites in the mitochondrial gene and carried out Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis using RNA-seq data for RCC and adrenal carcinoma. Furthermore, we confirmed the common mutation sites of mitochondrial genes in which the T3394Y (p.H30Y) site transitioned from histidine (His.; H) to tyrosine (Tyr.; Y) in the NADH dehydrogenase subunit 1 (ND1) gene. The R11,807G (p.T350A) site transitioned from threonine (Thr.; T) to alanine (Ala.; A). Additionally, the G15,438R or A (p.G231D) site transitioned from glycine (Gly.; G) to aspartic acid (Asp.; D) in cytochrome b (CYTB). Furthermore, pathway analysis, using RNA-seq, confirmed the common mutant pathway between RCC and adrenal carcinoma as cytokine–cytokine receptor (CCR) interaction. Confirmation of the original mutation sites suggests that transfer to AG may be related to the CCR interaction. Thus, during metastasis to the AG, mitochondria DNA mutation may represent the initial origin of the metastasis, followed by the likely mutation of the nuclear genes.